User:Pthakker1/Books/Biotherapeutics of Interest

Dr. Paresh Thakker

 * Abatacept
 * Abciximab
 * Adalimumab
 * Afelimomab
 * Afutuzumab
 * Alacizumab pegol
 * Alemtuzumab
 * Anifrolumab
 * Anrukinzumab
 * Apolizumab
 * Aselizumab
 * Atorolimumab
 * Basiliximab
 * Bectumomab
 * Belimumab
 * Benralizumab
 * Bertilimumab
 * Besilesomab
 * Bevacizumab
 * Bivatuzumab mertansine
 * Blinatumomab
 * BMS-945429
 * Brentuximab vedotin
 * Briakinumab
 * Brodalumab
 * Canakinumab
 * Carlumab
 * Catumaxomab
 * Cedelizumab
 * Certolizumab pegol
 * Cetuximab
 * Citatuzumab bogatox
 * Clazakizumab
 * Clenoliximab
 * Dacetuzumab
 * Daclizumab
 * Denosumab
 * Dupilumab
 * Eculizumab
 * Edrecolomab
 * Efalizumab
 * Eldelumab
 * Elsilimomab
 * Enokizumab
 * Epitope
 * Epratuzumab
 * Erlizumab
 * Ertumaxomab
 * Etanercept
 * Etaracizumab
 * Etrolizumab
 * Faralimomab
 * Fezakinumab
 * Fontolizumab
 * Foralumab
 * Fresolimumab
 * Fusion protein
 * Futuximab
 * Galiximab
 * Gavilimomab
 * Gemtuzumab ozogamicin
 * Gevokizumab
 * Golimumab
 * Gomiliximab
 * Guselkumab
 * Ibalizumab
 * Ibritumomab tiuxetan
 * Icrucumab
 * Inclacumab
 * Infliximab
 * Inolimomab
 * Inotuzumab ozogamicin
 * Intetumumab
 * Ipilimumab
 * Iratumumab
 * Itolizumab
 * Ixekizumab
 * Keliximab
 * Lambrolizumab
 * Lampalizumab
 * Lebrikizumab
 * Lemalesomab
 * Lerdelimumab
 * Ligelizumab
 * Lintuzumab
 * Lirilumab
 * List of monoclonal antibodies
 * Lorvotuzumab mertansine
 * Lucatumumab
 * Lumiliximab
 * Maslimomab
 * Matuzumab
 * Mavrilimumab
 * Mepolizumab
 * Metelimumab
 * Milatuzumab
 * Mogamulizumab
 * Monoclonal antibody
 * Monoclonal antibody therapy
 * Monospecific antibody
 * Morolimumab
 * Moxetumomab pasudotox
 * Muromonab-CD3
 * Namilumab
 * Natalizumab
 * Necitumumab
 * Nerelimomab
 * Nimotuzumab
 * Nivolumab
 * Ocaratuzumab
 * Ocrelizumab
 * Odulimomab
 * Ofatumumab
 * Olokizumab
 * Omalizumab
 * Oportuzumab monatox
 * Otelixizumab
 * Oxelumab
 * Ozoralizumab
 * Palivizumab
 * Panitumumab
 * Pascolizumab
 * Pateclizumab
 * Patritumab
 * Pegsunercept
 * Perakizumab
 * Pertuzumab
 * Pexelizumab
 * Pidilizumab
 * Placulumab
 * Polyclonal antibodies
 * Priliximab
 * PRO 140
 * Quilizumab
 * Ramucirumab
 * Ranibizumab
 * Reslizumab
 * Rituximab
 * Rontalizumab
 * Rovelizumab
 * Ruplizumab
 * Samalizumab
 * Sarilumab
 * Secukinumab
 * Sifalimumab
 * Siltuximab
 * Siplizumab
 * Sirukumab
 * Solitomab
 * Tabalumab
 * Tadocizumab
 * Talizumab
 * Taplitumomab paptox
 * Technetium (99mTc) fanolesomab
 * Technetium (99mTc) sulesomab
 * Telimomab aritox
 * Teneliximab
 * Teplizumab
 * Teprotumumab
 * TGN1412
 * Tildrakizumab
 * TNF inhibitor
 * TNX-650
 * Tocilizumab
 * Toralizumab
 * Tositumomab
 * Tovetumab
 * Tralokinumab
 * Trastuzumab
 * Tregalizumab
 * Tremelimumab
 * Tucotuzumab celmoleukin
 * Urelumab
 * Ustekinumab
 * Vapaliximab
 * Vatelizumab
 * Vedolizumab
 * Veltuzumab
 * Vepalimomab
 * Visilizumab
 * Volociximab
 * Vorsetuzumab mafodotin
 * Zalutumumab
 * Zanolimumab
 * Zatuximab
 * Zolimomab aritox